Clinical efficacy of Qizhidan Tongluo capsule in treating qi deficiency and blood stasis syndrome of non-acute ischemic stroke

doi:10.11817/j.issn.1673-9248.2023.03.007

Abstract

Abstract:

Objective

To evaluate the clinical efficacy and safety of Qizhidan Tongluo capsule in treating qi deficiency and blood stasis syndrome in patients with non-acute ischemic stroke.

Methods

A total of 205 patients were admitted to the Department of Encephalopathy of Yulin Hospital of Traditional Chinese Medicine from January 2020 to December 2021 and qualified for the diagnosis of Qi deficiency and blood stasis syndrome of non-acute ischemic stroke. They were divided into two groups randomly, including 103 patients in the treatment group and the other 102 patients in the control group. The two groups received the same primary treatment. The treatment group was treated additionally with Qizhidan tongluo capsules for 3 weeks. Neurological deficit score, TCM syndrome score (syndrome manifestations), and hemorheology were used to evaluate the effect in the two groups before and after treatment. Chi-square test and t-test were used to compare the differences of categorical and continuous variables between the treatment and control groups, respectively.

Results

NIHSS score in the treatment group was lower than that in the control group [(5.42±1.92) vs (7.53±1.67)], and the differences were statistically significant (t=8.395, P＜0.001); hemorheology was lower than that in the control group [whole blood viscosity (low cut): (10.85±1.19)mPa·a vs (12.25±1.53)mPa·a; whole blood viscosity (high cut): (6.61±0.97)mPa·a vs (7.42±0.93)mPa·a; plasma viscosity: (1.33±0.22)mPa·a vs (1.41±0.20)mPa·a], and the differences were statistically significant (t=7.344, 6.150, 2.615; P＜0.001, <0.001, =0.010]. The total effective rate of the treatment group was 86.41% (89/103), which was higher than that of the control group (74.51%, 76/102), and the differences were statistically significant (χ²=4.619, P=0.032). The adverse reaction rate during treatment in the two groups was 0.

Conclusion

Qizhidan Tongluo capsules can effectively improve the neurological function and hemorheology in patients with non-acute ischemic stroke type of Qi deficiency and blood stasis without obvious adverse reactions.

Key words: Apoplexy, Traditional Chinese medicine, Non-acute phase, Qi deficiency and blood stasis, Qizhidan Tongluo capsule

Zhiwei Xu, Huihua Liu, Weizhao Qin, Guiyu Feng, Xian Li, Cui Qin, Jiejie Lin, Guohui. Liang. Clinical efficacy of Qizhidan Tongluo capsule in treating qi deficiency and blood stasis syndrome of non-acute ischemic stroke[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(03): 232-236.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnxgbzz.cma-cmc.com.cn/EN/10.11817/j.issn.1673-9248.2023.03.007

https://zhnxgbzz.cma-cmc.com.cn/EN/Y2023/V17/I03/232

Figures/Tables 4

组别	例数	男/女（例）	年龄（岁， $x ¯$ ±s）	病程（d， $x ¯$ ±s）	高血压（例）	糖尿病（例）	高脂血症（例）
治疗组	103	65/38	59.79±8.54	45.44±7.97	45	36	22
对照组	102	61/41	60.68±8.94	44.35±7.66	41	34	27
统计值		χ²=0.236	t=0.729	t=0.993	χ²=0.257	χ²=0.060	χ²=0.736
P值		0.627	0.467	0.322	0.612	0.807	0.391

组别	例数	男/女（例）	年龄（岁， $x ¯$ ±s）	病程（d， $x ¯$ ±s）	高血压（例）	糖尿病（例）	高脂血症（例）
治疗组	103	65/38	59.79±8.54	45.44±7.97	45	36	22
对照组	102	61/41	60.68±8.94	44.35±7.66	41	34	27
统计值		χ²=0.236	t=0.729	t=0.993	χ²=0.257	χ²=0.060	χ²=0.736
P值		0.627	0.467	0.322	0.612	0.807	0.391

组别	例数	基本恢复	显著进步	稍进步	进步	无变化	恶化	总有效率（%）
治疗组	103	5	9	36	39	14	0	86.41
对照组	102	3	6	15	52	26	0	74.51
χ²值								4.619
P值								0.032

组别	例数	治疗前	治疗后	t值	P值
治疗组	103	10.66±2.37	5.42±1.92	16.345	＜0.001
对照组	102	11.06±3.01	7.53±1.67	10.824	＜0.001
t值		1.055	8.395
P值		0.293	＜0.001

组别	时间	全血黏度（低切）	全血黏度（高切）	血浆黏度
治疗组	治疗前	13.54±1.46^a	8.64±1.21^a	1.50±0.29^a
治疗组	治疗后	10.85±1.19^b	6.61±0.97^b	1.33±0.22^b
对照组	治疗前	13.68±1.58	8.38±1.24	1.48±0.27
对照组	治疗后	12.25±1.53	7.42±0.93	1.41±0.20
t值^a		0.635	1.491	0.406
P值^a		0.526	0.137	0.685
t值^b		7.344	6.150	2.615
P值^b		＜0.001	＜0.001	0.010

References 16

1	贾建平, 陈生弟. 神经病学 [M]. 7版. 北京: 人民卫生出版社, 2013: 170.
2	王拥军, 李子孝, 谷鸿秋, 等. 中国卒中报告2020(中文版)(1) [J]. 中国卒中杂志, 2022, 17(5): 433-447.
3	国家中医药管理局脑病急症协作组. 中风症诊断与疗效评定标准(试行) [J]. 北京中医药大学学报, 1996, 19(1): 55-56.
4	李小刚, 杨东东, 胡波, 等. 脑脉利颗粒对急性缺血性卒中的临床疗效评价 [J]. 中国卒中杂志, 2021, 16(10): 1011-1015.
5	强茗, 胡元娟. 益气通络汤对气虚血瘀型脑梗死患者功能恢复的作用研究 [J]. 实用医院临床杂志, 2021, 18(4): 12-15.
6	谭秀芬, 李颖骥, 张明明, 等. 偏瘫通络汤联合针刺治疗缺血性中风偏瘫(气虚血瘀)随机平行对照研究 [J]. 实用中医内科杂志, 2018, 32(6): 44-46.
7	郑淑美. 明清医家对中风治疗的认识 [J]. 中医药学刊, 2004, 22(2): 272-273.
8	罗飘, 楚世峰. 黄芪在脑卒中的临床药理学及机制研究 [J]. 神经药理学报, 2018, 8(6): 42.
9	赵红. 川芎的鉴定方法及药理分析与临床应用 [J]. 光明中医, 2021, 36(10): 1730-1732.
10	赵全如, 谢晓燕. 丹参的化学成分及药理作用研究进展 [J]. 广东化工, 2021, 48(1): 57-59.
11	高玲, 赵建军, 李艳艳, 等. 地龙治疗缺血性脑卒中作用机制的现代研究进展 [J]. 时珍国医国药, 2019, 30(2): 446-448.
12	黄秋阳, 冷静, 甘奇超, 等. 水蛭及其制剂在心脑血管疾病中的应用 [J]. 中成药, 2019, 41(8): 1915-1920.
13	张晓莹, 郭宏伟. 石菖蒲药理作用研究进展 [J]. 中国中医药科技, 2019, 26(2): 320-321.
14	李晓青, 赵佳奇, 田雅娟, 等. 远志、石菖蒲及其对药改善记忆的物质基础和作用机制研究进展 [J]. 中国实验方剂学杂志, 2019, 25(3): 190-199.
15	蔡琳. 葛根的化学成分、药理及临床作用的研究进展 [J]. 山东化工, 2014, 43(8): 40-41.
16	安鑫, 张连运, 逄艳, 等. 加减小续命汤治疗急性进展性缺血性中风30例 [J]. 光明中医, 2019, 34(18): 2800-2803.

[1]	Hongxing Chen, Lijun Zhang, Yong Zhang, Hu Li, Chi Zhou, Yinuo Fan. Meta-analysis of effect of external application of traditional Chinese medicine after arthroscopic debridement in knee osteoarthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 663-672.
[2]	Wei Yang, Xia Hao, Dongzhen Zhu, Jinbo Zhang, Xuefei Tian, Bin Yao. A meta analysis of the clinical effect of traditional Chinese medicine on burn and scald patients [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(05): 419-426.
[3]	Yue Liao, Ke Wang, Jiangyue Qin, Yanqiu Wu, Jun Chen, Tao Wang, Fuqiang Wen, Hao Wang. Efficacy of Danlong oral liquid in treatment of mild-to-moderate acute exacerbation of chronic obstructive pulmonary disease: A multicenter, prospective, observational cohort study [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(03): 306-311.
[4]	Lu Wang, Chuyue Huang, Zhili Li. Establishment of patient-derived colorectal cancer organoids and application in evaluating the anti-cancer activity of toxic monomers of traditional Chinese medicines [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(04): 343-348.
[5]	Junqiao Shao, Ming Wang. Treatment of sleep disorders in maintenance hemodialysis patients with traditional Chinese medicine [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(02): 97-100.
[6]	Xinli Xu, Xiaoyong Yu. Epigenetics: a new perspective of traditional Chinese medicine in the treatment of diabetic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 276-280.
[7]	Chao Sheng, Bin Zhou. Effect of low frequency electric stimulation of laryngeal muscles on dysphagia after stroke and quality of life [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(05): 279-284.
[8]	Shihao Ni, Xiaoming Dong, Haohui Liu, Xingling He, Donghua Liu, Ziru Li, Sijing Li, Yanhui Jiang, Jie Huang, Xiaojiao Zhang, Lu Lu, Zhongqi Yang. Analysis of clinical evidence for traditional Chinese medicines to treat corona virus disease 2019 [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1253-1269.
[9]	Siqi Yang, Tianmeng Wang, Yaoguang Wang. Clinical efficacy and safety of Huobahuagen tablets combined with Yishen Xiaozhuo formula in treating chronic glomerulonephritis with spleen-kidney qi deficiency and damp turbidity syndrome [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1241-1246.
[10]	Sugui Wang, Liyuan Huang, Fujin Jiang, Ziyu Wu, Xianyun Zhang, Qiang Li, Dali Yan. Role of HNRNPA2B1 in prostate cancer and screening of HNRNPA2B1-targeted active components of traditional Chinese medicine [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 731-736.
[11]	Chunguo Xing, Yingqiu Xia, Yunxia Liao, Ning Zhao, Ran Tao. Informatization construction of public health in primary medical institutions in Jiangsu Province [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(12): 1201-1206.
[12]	Chaojun Zheng, Hongnian Wang, Yuhu Jia, Qisheng Hu. Comparison of clinical efficacy of NSAIDs alone and in combination with Fangfeng decoction in treatment of knee osteoarthritis in elderly patients [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(04): 343-348.
[13]	Cuicui Ma, Nan Li, Manli Wang, Cheng Wang, Xu Zhang. Recent research advances in nocturnal enuresis treated by traditional Chinese medicine [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2022, 11(04): 168-170.
[14]	Youtao Ge, Qiuzi Jiang, Tingsong Bian, Qianqian Xiao. Study on the law of formation and molecular mechanism of traditional Chinese medicine in treating late-onset hypogonadism in male [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(03): 43-50.
[15]	Ning’an Shuai, Yue Ma, Yuting Qiang, Xiaolan Shi, Li Tong, Weijing Dong. Efficacy of hyperbaric oxygen therapy combined with directional drug penetration treatment of traditional Chinese Medicine on diabetic peripheral neuropathy in elderly patients [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2022, 09(03): 29-32.

Please choose a citation manager

Content to export